ADAGE CAPITAL PARTNERS GP, L.L.C. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 88 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
ADAGE CAPITAL PARTNERS GP, L.L.C. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$5,888,209
+743.6%
438,437
+776.9%
0.01%
+550.0%
Q3 2022$698,000
-57.1%
50,000
-50.0%
0.00%
-33.3%
Q1 2022$1,627,000
-91.9%
100,000
-91.9%
0.00%
-91.7%
Q4 2021$20,086,000
-23.8%
1,233,000
+124.2%
0.04%
-46.3%
Q2 2020$26,351,000
-0.6%
550,000
+65.1%
0.07%
+1.5%
Q2 2019$26,505,000
-53.1%
333,100
-34.0%
0.07%
-53.2%
Q1 2019$56,489,000
+306.1%
505,000
+265.9%
0.14%
+261.5%
Q4 2018$13,909,000
+8.9%
138,000
+79.2%
0.04%
+11.4%
Q3 2015$12,771,000
-39.2%
77,000
-11.5%
0.04%
-32.7%
Q2 2015$21,000,000
-33.5%
87,000
-22.3%
0.05%
-32.5%
Q1 2015$31,579,000
+68.7%
111,975
-6.7%
0.08%
+67.4%
Q4 2014$18,720,000
+92.9%
120,000
+192.7%
0.05%
+91.7%
Q3 2014$9,704,000
+173.4%
41,000
+173.3%
0.02%
+166.7%
Q2 2014$3,549,000
-80.5%
15,000
-72.9%
0.01%
-82.0%
Q1 2014$18,226,000
+52.5%
55,264
-68.4%
0.05%
+56.2%
Q4 2013$11,949,000
-57.8%
175,000
-57.4%
0.03%
-60.5%
Q3 2013$28,348,000
+44.2%
410,655
-6.3%
0.08%
+32.8%
Q2 2013$19,659,000
+82.2%
438,434
+52.0%
0.06%
+69.4%
Q1 2013$10,787,000288,4340.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2013
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders